Novartis is set to pay as much as $39 biliion to buy a controlling stake in Alcon, a Houston company that dominates the eye care market.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.